戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Mtb does not encode any characterized cobalamin transpor
2                                              Mtb extract, but not SL-1, also stimulates non-nocicepti
3                                              Mtb organic extracts from mutants lacking SL-1 synthesis
4                                              Mtb protein tyrosine phosphatase B (mPTPB) is a virulenc
5                                             (Mtb) produces inflections in the host signaling networks
6                                              Mtb- specific antigens and live bacillus Calmette-Guerin
7     TNF-alpha is responsible for accelerated Mtb growth, and TNF-alpha neutralisation reverses augmen
8 se in TB, and inhibition of PD-1 accelerates Mtb growth via excessive TNF-alpha secretion.
9  we demonstrate in vivo activity in an acute Mtb infection model and provide further proof of DprE1 b
10            Infection with laboratory-adapted Mtb H37Rv resulted in granulomas that are characterized
11 and confer superior immunity against aerosol Mtb infection in the context of T2D.
12  = 0.56), based on an IFNgamma readout after Mtb antigen stimulation.
13          The compound shows activity against Mtb H37Rv residing in macrophages.
14  confers protective trained immunity against Mtb.
15 s of selenium nanoparticles (Se NPs) against Mtb and further introduce a novel nanomaterial-assisted
16 ion, provided substantial protection against Mtb infection, emphasizing the importance of delivery ro
17 to identify correlates of protection against Mtb infection.
18 id not confer significant protection against Mtb K.
19 tion correlates of immune protection against Mtb.
20 xamining how drug-resistance mutations alter Mtb physiology and differences in the immune response to
21                                     Although Mtb can synthesize vitamin B(12) (cobalamin) de novo, up
22                                           An Mtb mutant lacking SL-1, MtbDeltapks2, shows attenuated
23                        Here, we show that an Mtb organic extract activates nociceptive neurons in vit
24 tegy manipulating antimicrobial immunity and Mtb clearance may potentially serve in more effective th
25 anti-Mtb LAM immunoglobulin M (IgM) and anti-Mtb LAM IgG respectively.
26 cient size generally provide for potent anti-Mtb activity of these dihydropyridomycins (minimum inhib
27                           Moreover, the anti-Mtb LAM IgM bound sensor probes and the AuNP reagent sto
28               This indicates that their anti-Mtb activity does not critically depend on the inhibitio
29 monic (AuNP) labels functionalized with anti-Mtb LAM immunoglobulin M (IgM) and anti-Mtb LAM IgG resp
30  distinguishing between ATB and asymptomatic Mtb-infected latent individuals.
31 tinguish active TB disease from asymptomatic Mtb infection.
32  TNF-alpha neutralisation reverses augmented Mtb growth caused by anti-PD-1 treatment.
33 ving into lysosome-associated autophagosomal Mtb degradation linked to ROS-mitochondrial and PI3K/Akt
34                                  P-FAB based Mtb LAM sensor demonstrates its potential for an on-site
35 rates that the metabolic differences between Mtb-infected AMs and KCs lead to differences in the rest
36  Overall, this study provides a link between Mtb infection, epigenetics and host immune response, whi
37 stallography of four apo- and cofactor-bound Mtb-MenD structures, along with several spectroscopy ass
38 e exacerbation of HIV-1 infection induced by Mtb.
39 ption of human immune signaling molecules by Mtb remains elusive, limiting drug discovery.
40 uired for heme and hemoglobin utilization by Mtb.
41   These findings support the use of clinical Mtb HN878 strain for infection in mice as an appropriate
42 correlation of genetic diversity of clinical Mtb isolates with clinically important phenotypes such a
43                              Here we compare Mtb growth in mouse alveolar (AMs), peritoneal (PMs), an
44 -mediated clearance of bacteria.Conclusions: Mtb can persist in asymptomatic macaques for at least 7
45 rowth, some granulomas are unable to control Mtb growth, leading to bacteria and infected cells leavi
46  mice infected with an ULD or a conventional Mtb dose (50-100 CFU) that correlated with lung bacteria
47                          The antitoxin, DarG(Mtb) , forms a cytosolic complex with DNA-repair protein
48 Rv0060 (DNA ADP-ribosyl glycohydrolase, DarG(Mtb) ), functions along with its cognate toxin Rv0059 (D
49 imultaneous deletion of both darT(Mtb) -darG(Mtb) does not alter viability of Mtb in vitro or in mice
50          We demonstrate that DarT(Mtb) -DarG(Mtb) form a functional TA pair and essentiality of darG(
51                            Depletion of DarG(Mtb) alone is bactericidal, a phenotype that is rescued
52  functional TA pair and essentiality of darG(Mtb) is dependent on the presence of darT(Mtb) , but sim
53                    Partial depletion of DarG(Mtb) triggers a DNA-damage response and sensitizes Mtb t
54 is essential for Mtb to survive partial DarG(Mtb) -depletion and leads to a hypermutable phenotype.
55 tb) , but simultaneous deletion of both darT(Mtb) -darG(Mtb) does not alter viability of Mtb in vitro
56  that assembles independently of either DarT(Mtb) or interaction with DNA.
57 rG(Mtb) is dependent on the presence of darT(Mtb) , but simultaneous deletion of both darT(Mtb) -darG
58                     We demonstrate that DarT(Mtb) -DarG(Mtb) form a functional TA pair and essentiali
59 in Rv0059 (DNA ADP-ribosyl transferase, DarT(Mtb) ), to mediate reversible DNA ADP-ribosylation (Jank
60       Instead of the classical ATM-Chk2 DDR, Mtb gains survival advantage through ATM-Akt signaling c
61  of early alveolar macrophages and decreased Mtb control.
62 c experiments with clpC1- and clpP2-depleted Mtb cells suggested that the ClpC1P1P2 complex criticall
63 ork in concert with host immunity to disable Mtb.
64           Therefore, by using C10 to dissect Mtb persistence, we discovered that INH resistance is no
65 r after the loss of the MmpS6/MmpL6-encoding Mtb-specific deletion 1 region (TbD1).
66  powerful new tool that can rapidly evaluate Mtb drug resistance in a laboratory setting.
67                                 Pre-existing Mtb infection creates an immunological environment that
68 on, and we investigated whether pre-existing Mtb infection impacts the susceptibility of CD4+ T cells
69 and molecular insights into how pre-existing Mtb infection influences HIV-1 pathogenesis.
70          However, the impact of pre-existing Mtb infection on subsequent HIV infection has not been f
71                               Experimentally Mtb-infected non-human primates (NHP) mirror the disease
72                                     Finally, Mtb-infected guinea pigs cough in a manner dependent on
73 hanistically, we demonstrate that, following Mtb infection, S100A8/A9 expression is required for upre
74 ral GSMNs networks have been constructed for Mtb and used to study the complex relationship between t
75  of the DNA-damage response is essential for Mtb to survive partial DarG(Mtb) -depletion and leads to
76 tify SR-B1 as the airway M cell receptor for Mtb.
77                        SR-B1 is required for Mtb binding to and translocation across M cells in mouse
78 B (mPTPB) is a virulence factor required for Mtb survival in host macrophages.
79 emonstrate a previously undescribed role for Mtb EsxA in mucosal invasion and identify SR-B1 as the a
80 contrast to Pam(3)CSK(4) and FSL-1, we found Mtb LAM did not induce any of the classical PMN priming
81 r, both CD4(+) and CD8(+) T lymphocytes from Mtb infected, metformin treated animals maintained a mor
82 demonstrate that, unlike BCG or beta-glucan, Mtb reprograms HSCs via an IFN-I response that suppresse
83                                         HadD(Mtb) deletion triggered a marked change in Mtb keto-MA c
84                            Importantly, HadD(Mtb) has a strong impact on Mtb virulence in the mouse m
85              The effects of the lack of HadD(Mtb) observed both in vitro and in vivo designate this p
86 letion mutant revealed the influence of HadD(Mtb) on the planktonic growth, colony morphology and bio
87 scovery of a third dehydratase protein, HadD(Mtb) (Rv0504c), whose gene is non-essential and sits ups
88        These data strongly suggest that HadD(Mtb) catalyzes the 3-hydroxyacyl dehydratation step of l
89 aries tested and get outside of the historic Mtb property space if we are to generate novel improved
90 3-ionized form using an arginine, Arg199, in Mtb.
91 D(Mtb) deletion triggered a marked change in Mtb keto-MA content and size distribution, deeply impact
92 n addition to validating the role of ClpB in Mtb's response to oxidants, we show that HtpG, a homolog
93 P2 protease subunits are well-established in Mtb, but the potential roles of the associated unfoldase
94 t clinical Rif(R) RNAP substitution found in Mtb infected patients (S456>L of the beta subunit).
95 tify the genes that support clpB function in Mtb.
96                              Furthermore, in Mtb specific T cells, SIRT2 deacetylates NFkappaB-p65 at
97           Similar changes were identified in Mtb following antibiotic-treatment, and MDR-Mtb as mecha
98                   Cell activation markers in Mtb-specific CD4+T cells distinguished ATB from LTBI and
99 imidazole are two top-scoring metabolites in Mtb-infected KCs and that acetylcholine is the top-scori
100 asis of various growth-essential proteins in Mtb, several of which contain intrinsically disordered r
101 oteins are targets for T-cell recognition in Mtb.
102 ce and an anticipatory metabolic response in Mtb.
103 and that acetylcholine is the top-scoring in Mtb-infected AMs.
104 d, decreased disease pathology and increased Mtb-specific protective immune responses.
105      Inhibition of PD-1 signalling increases Mtb growth, and augments cytokine secretion.
106 od from Mycobacterium tuberculosis-infected (Mtb-infected) individuals with and without HIV coinfecti
107          In the chronic stages of infection, Mtb infected metformin-treated animals had restored syst
108 d atropine (acetylcholine inhibitor) inhibit Mtb growth in AMs.
109 statin and mevastatin were unable to inhibit Mtb growth in THP-1 cells.
110                               Interestingly, Mtb LAM did not abrogate priming responses elicited by P
111 d autophagy whereas imidazole directly kills Mtb by reducing cytochrome P450 activity.
112 t loss of TbD1 at the origin of the L2/L3/L4 Mtb lineages was a key driver for their global epidemic
113 ould discriminate active disease from latent Mtb infection (LTBI).
114 T cells derived from individuals with latent Mtb infection supported more efficient HIV-1 transcripti
115 g with ligands from bacterial pathogens like Mtb, may be important for early recognition of infected
116 avenous BCG prevents or substantially limits Mtb infection in highly susceptible rhesus macaques has
117                     Infection with the LprE (Mtb) mutant also led to accumulation of autophagy-relate
118 d these mechanisms are among circulating MDR Mtb strains and what impact drug-resistance-conferring m
119  Mtb following antibiotic-treatment, and MDR-Mtb as mechanisms to circumvent antibiotic effects.
120 of ATM inhibitor enhances isoniazid mediated Mtb clearance in macrophages as well as in murine infect
121                                    Moreover, Mtb LAM did not elicit p38 MAPK phosphorylation or endoc
122           Reduced trafficking of this mutant Mtb strain to lysosomes correlated with enhanced intrace
123 iod but diverged for LTBI prevalence and new Mtb infections-outcomes for which definitive data are un
124         The recent discovery of a set of new Mtb inhibitory compounds that target Mtb-fumarase by bin
125 ls across the Mtb infection spectrum and non-Mtb-infected control individuals were analyzed for infla
126                                     Notably, Mtb infected CSE(-/-) macrophages show increased flux th
127 n of 3,724 distinct proteins covering 95% of Mtb protein-coding genes using artificial antigen-presen
128 human cohorts, demonstrating associations of Mtb bacteremia with progressive phenotypes of latent inf
129 were infected via inhalation with ~10 cfu of Mtb CDC1551, after which asymptomatic animals were eithe
130 o assess 3HP treatment-mediated clearance of Mtb infection in latently infected macaques.Methods: Six
131 dentify the epitopes targeted by clusters of Mtb-specific T cells, we carried out a screen of 3,724 d
132                 A metabolomics comparison of Mtb-infected macrophages indicates that ornithine and im
133 istic lysosomal and Isoniazid destruction of Mtb.
134 ug-induced and phagolysosomal destruction of Mtb.
135 lth threat worldwide, and the development of Mtb vaccines could play a pivotal role in the prevention
136       While this lipid promotes the entry of Mtb into macrophages, which occurs via phagocytosis, its
137                         Further, exposure of Mtb to H(2)S regulates genes involved in sulfur and copp
138 st lysosomal system is a defining feature of Mtb-infected macrophages and suggest that this altered l
139 Se/Man-Se NPs further promoted the fusion of Mtb into lysosomes for synergistic lysosomal and Isoniaz
140                                Two groups of Mtb-exposed contacts of tuberculosis (TB) patients were
141 ndispensable for the extracellular growth of Mtb and for its survival in macrophages.
142 xyacyl-ACP dehydratases, HadAB and HadBC, of Mtb FAS-II complex required in-depth work.
143                  Granulomas, the hallmark of Mtb infection, are complex structures that form in lungs
144 naphthoic acid (DHNA), binds to domain II of Mtb-MenD and inhibits its activity.
145 (3)CSK(4) We speculate that the inability of Mtb LAM to prime PMN may be due to differential localiza
146 at H(2)S reverses *NO-mediated inhibition of Mtb respiration.
147  resistance in cultured clinical isolates of Mtb and benchmark its performance with standard minimum
148 eight recently published metabolic models of Mtb-H37Rv to facilitate model choice.
149  profoundly alters the protective outcome of Mtb challenge in non-human primates (Macaca mulatta).
150                               Phenotyping of Mtb hadD deletion mutant revealed the influence of HadD(
151 Cs lead to differences in the restriction of Mtb growth.
152 ts that DSBs inflicted by SecA2 secretome of Mtb provides survival niche through activation of ATM ki
153  NPs also induced autophagy sequestration of Mtb, evolving into lysosome-associated autophagosomal Mt
154 with aerosol exposure to the H37Rv strain of Mtb.
155 both drug-sensitive and resistant strains of Mtb and enhances the efficacy of front line anti-TB drug
156  insights into how drug-resistant strains of Mtb differentially impact immunometabolism.
157 shown that certain drug-resistant strains of Mtb modulate host metabolic reprogramming, and therefore
158  an unanticipated immune evasion strategy of Mtb in the BM that controls the magnitude and intrinsic
159 nal, structural, and bioinformatics study of Mtb enzymes initiating cholesterol catabolism and demons
160 d show Mpy-dependent antibiotic tolerance of Mtb in mouse lungs.
161  findings and show that in vivo treatment of Mtb-infected C57BL/6 mice with doramapimod, a p38 MAP-ki
162 (Mtb) -darG(Mtb) does not alter viability of Mtb in vitro or in mice.
163 ortion of memory T-cell subsets depending on Mtb infection status.
164               Siglec-1 expression depends on Mtb-induced production of type I interferon (IFN-I).
165 mportantly, HadD(Mtb) has a strong impact on Mtb virulence in the mouse model of infection.
166 B) strategy for mannosylated LAM (Man-LAM or Mtb LAM) detection down to attomolar concentrations.
167 tomatic for 7 months but harbored persistent Mtb infection, as shown by reactivation of latent infect
168 nce for 3HP-mediated clearance of persistent Mtb infection in human lungs has not been established.Ob
169 onal nanomaterials to promote phagolysosomal Mtb clearance remains a big challenge.
170 ed with lung bacterial burdens and predicted Mtb infection outcomes across species, including risk of
171                       Models found prevalent Mtb infection and migration to be more significant drive
172 eatures with human granulomas, and prolonged Mtb containment with unilateral pulmonary infection in s
173                       However, how pulmonary Mtb infection causes cough remains undefined, and whethe
174      The emergence of Rif-resistant (Rif(R)) Mtb presents a need for new antibiotics.
175 at pharmacological inhibition of CBS reduces Mtb bacillary load in mice.
176 s an immunological environment that reflects Mtb infection status and influences the susceptibility o
177 at H(2)S is the effector molecule regulating Mtb survival in macrophages.
178 programming in the context of drug-resistant Mtb infection, previous literature examining how drug-re
179 ces in the immune response to drug-resistant Mtb provides significant insights into how drug-resistan
180                                 KCs restrict Mtb growth more efficiently than all other macrophages a
181 e or imidazole or the two together restricts Mtb growth.
182 riggers a DNA-damage response and sensitizes Mtb to drugs targeting DNA metabolism and respiration.
183                 Ribonucleic acid sequencing, Mtb proteome arrays, and metabolic profiling were perfor
184 spectrometry establish that H(2)S stimulates Mtb respiration and bioenergetics predominantly via cyto
185                 A powerful approach to study Mtb metabolism as a whole, rather than just individual e
186                       In this work, we study Mtb metabolism of lactate and pyruvate combining classic
187                                  In summary, Mtb LAM activates PMN via TLR2/1, resulting in the produ
188  of new Mtb inhibitory compounds that target Mtb-fumarase by binding to a nonconserved allosteric sit
189 sion of other chaperones, demonstrating that Mtb's stress response network depends upon finely tuned
190                         We hypothesized that Mtb infection creates an immunological environment that
191                    Our results indicate that Mtb exploits host-derived H(2)S to promote growth and di
192                           Here, we show that Mtb has an itaconate dissimilation pathway and that the
193                           Here, we show that Mtb upregulates one of the key epigenetic modulators, NA
194                            Here we show that Mtb-infected mice deficient in the H(2)S-producing enzym
195                               We showed that Mtb-infected CSE(-/-) mice survive longer than WT mice,
196  of suppression of immunity and suggest that Mtb has its own transformation system resembling the hum
197 vironment changes as we age and suggest that Mtb may benefit from declining host defenses in the lung
198 nes a confluence of findings supporting that Mtb has restricted metabolism at acidic pH that results
199                                          The Mtb cell wall cording factor, trehalose 6,6'-dimycolate
200                                          The Mtb LAM is quantified in terms of absorption of light pa
201 ted from HIV-negative individuals across the Mtb infection spectrum and non-Mtb-infected control indi
202 o study the complex relationship between the Mtb genotype and its phenotype.
203 atification could be further improved by the Mtb Ag/BCG IFNgamma ratio (p < 0.0001 AUC = 0.91).
204 ociceptive neurons in vitro and identify the Mtb glycolipid sulfolipid-1 (SL-1) as the nociceptive mo
205 show that M cell transcytosis depends on the Mtb Type VII secretion machine and its major virulence f
206 es and non-IFN-gamma T cell responses to the Mtb-specific proteins ESAT6 and CFP10, immunologic evide
207 al compartments that share features with the Mtb intracellular compartment.
208  recruited and classified according to their Mtb infection status using the tuberculin skin test (TST
209 ere we show that deletion of TbD1 confers to Mtb a significant increase in resistance to oxidative st
210  A (SP-A) and surfactant protein D (SP-D) to Mtb.
211             We demonstrated that exposure to Mtb directs primary human CD34(+) cells to differentiate
212 d CFP10, immunologic evidence of exposure to Mtb.
213 ron axis in HSCs impairs trained immunity to Mtb infection.
214 evelopment of protective trained immunity to Mtb.
215                  However, exposure of PMN to Mtb LAM did elicit pro- and anti-inflammatory cytokine p
216 etformin promotes natural host resistance to Mtb infection by maintaining immune cell metabolic homeo
217 ously associated with the immune response to Mtb and demonstrates the power of high-throughput analys
218 sights into the early protective response to Mtb infection and possible avenues to interfere with Mtb
219       The proinflammatory immune response to Mtb infection in untreated guinea pigs was associated wi
220 F-alpha, and IFN-gamma levels in response to Mtb infection.
221  computational model, MultiGran, that tracks Mtb infection within multiple granulomas in an entire lu
222 olic flux profiles indicate that BDQ-treated Mtb is dependent on glycolysis for ATP production, opera
223 sotopomer analysis, we show that BDQ-treated Mtb redirects central carbon metabolism to induce a meta
224 that lipoarabinomannan from M. tuberculosis (Mtb LAM) would prime human PMN in a TLR2-dependent manne
225 ntly relies on detection of M. tuberculosis (Mtb).
226                  Mycobacterium tuberculosis (Mtb) and human immunodeficiency virus (HIV) coinfection
227  to ribosomes in Mycobacterium tuberculosis (Mtb) and show Mpy-dependent antibiotic tolerance of Mtb
228 ly infected with Mycobacterium tuberculosis (Mtb) and to group them according to their specificity.
229                  Mycobacterium tuberculosis (Mtb) can enter the body through multiple routes, includi
230 robial-resistant Mycobacterium tuberculosis (Mtb) causes over 200,000 deaths each year.
231                  Mycobacterium tuberculosis (Mtb) continues to be a major health threat worldwide, an
232 lted in improved Mycobacterium tuberculosis (Mtb) control during chronic but not acute TB.
233 The viability of Mycobacterium tuberculosis (Mtb) depends on energy generated by its respiratory chai
234 termined whether Mycobacterium tuberculosis (Mtb) directly regulates myeloid commitment.
235 stance, with new Mycobacterium tuberculosis (Mtb) drugs having the highest priority.
236 r persistence of Mycobacterium tuberculosis (Mtb) during asymptomatic latent tuberculosis infection (
237                  Mycobacterium tuberculosis (Mtb) employs plethora of mechanisms to hijack the host d
238 sis (TB) are the Mycobacterium tuberculosis (Mtb) escape from phagolysosomal destruction and limited
239 s expressing the Mycobacterium tuberculosis (Mtb) ESX-1 secretion system (BCG::RD1 and BCG::RD1 ESAT-
240 e human pathogen Mycobacterium tuberculosis (Mtb) harbors a well-orchestrated Clp (caseinolytic prote
241  "hypervirulent" Mycobacterium tuberculosis (Mtb) HN878 induces human-like granulomas composed of bac
242 e in controlling Mycobacterium tuberculosis (Mtb) infection and disease progression.
243 TB) is caused by Mycobacterium tuberculosis (Mtb) infection and is a major public health problem.
244 egies to prevent Mycobacterium tuberculosis (Mtb) infection are urgently required.
245                  Mycobacterium tuberculosis (Mtb) infection causes tuberculosis (TB), a disease chara
246 Murine models of Mycobacterium tuberculosis (Mtb) infection demonstrate progression of M1-like (proin
247                  Mycobacterium tuberculosis (Mtb) infection is among top ten causes of death worldwid
248 a consequence of Mycobacterium tuberculosis (Mtb) infection, contributes to TB pathogenesis, and when
249 85A expressed by Mycobacterium tuberculosis (Mtb) is a bacterial surface protein that is commonly use
250                  Mycobacterium tuberculosis (Mtb) is an obligate human pathogen and the causative age
251 dissemination of Mycobacterium tuberculosis (Mtb) is critical to the pathogenesis of progressive tube
252  adaptability of Mycobacterium tuberculosis (Mtb) is still unresolved.
253                  Mycobacterium tuberculosis (Mtb) is the leading cause of death from infection worldw
254 ound in clinical Mycobacterium tuberculosis (Mtb) isolates phenocopy lepA deletion to varying degrees
255  (TB), caused by Mycobacterium tuberculosis (Mtb) latently infects approximately one-fourth of the wo
256 role of H(2)S in Mycobacterium tuberculosis (Mtb) pathogenesis.
257 mice can control Mycobacterium tuberculosis (Mtb) replication, they have exacerbated inflammation and
258                  Mycobacterium tuberculosis (Mtb) strains are classified into different phylogenetic
259  of ligands from Mycobacterium tuberculosis (Mtb) to MAIT cells.
260  interruption of Mycobacterium tuberculosis (Mtb) transmission, 2) sustained resolution of LTBI and T
261 hanisms by which Mycobacterium tuberculosis (Mtb) worsens HIV-1 pathogenesis remain scarce.
262 ive agent of TB, Mycobacterium tuberculosis (Mtb), and therefore metabolic pathways have recently re-
263 une responses to Mycobacterium tuberculosis (Mtb), as adjunctive treatment given with antitubercular
264 isease caused by Mycobacterium tuberculosis (Mtb), manifests with a persistent cough as both a primar
265 is infected with Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB).
266                  Mycobacterium tuberculosis (Mtb), the causative infectious agent of tuberculosis (TB
267  In the pathogen Mycobacterium tuberculosis (Mtb), the protective effect of chaperones extends to sur
268 cterial pathogen Mycobacterium tuberculosis (Mtb), three contain antitoxins essential for bacterial v
269 ess responses in Mycobacterium tuberculosis (Mtb)-infected host cells.
270  is expressed in Mycobacterium tuberculosis (Mtb)-infected lung tissue but is absent in areas of immu
271 ally elevated in Mycobacterium tuberculosis (Mtb)-infected macrophages.
272  al. find that a Mycobacterium tuberculosis (Mtb)-specific lipid, SL-1, stimulates human nociceptive
273 rs cell death in Mycobacterium tuberculosis (Mtb).
274 by the bacterium Mycobacterium tuberculosis (Mtb).
275 with aerosolized Mycobacterium tuberculosis (Mtb).
276 ssion of InhA in Mycobacterium tuberculosis (Mtb).
277 e human pathogen Mycobacterium tuberculosis (Mtb).
278 icity factors of Mycobacterium tuberculosis (Mtb).
279 g populations of Mycobacterium tuberculosis (Mtb).
280 fections such as Mycobacterium tuberculosis (Mtb).
281  on detection of Mycobacterium tuberculosis (Mtb).
282  by the pathogen Mycobacterium tuberculosis (Mtb).
283 ical isolates of Mycobacterium tuberculosis (Mtb).
284 ors of ThyX from Mycobacterium tuberculosis (Mtb).
285 co-infected with Mycobacterium tuberculosis (Mtb)/simian immunodeficiency virus (SIV) suggests that c
286 r tenfold more hits than screening wild-type Mtb alone, with chemical-genetic interactions providing
287 emonstrating that Sor inhibits the wild-type Mtb RNAP by a similar mechanism as Rif: by preventing th
288 TAX1BP1, mediates clearance of ubiquitylated Mtb and targets bacteria to LC3-positive phagophores.
289 inant analyses to validate an approach using Mtb-specific CD4+T-cell activation markers in blood to d
290  of light membranes from Pam(3)CSK(4) versus Mtb LAM-stimulated cells demonstrated differential patte
291                                 The virulent Mtb strain, Rv caused double strand breaks (DSBs), where
292 tion, macaques were challenged with virulent Mtb.
293                          Similarly, in vitro Mtb infection of macrophages resulted in reduced colony
294  causes cough remains undefined, and whether Mtb produces a neuron-activating, cough-inducing molecul
295  population is estimated to be infected with Mtb, accounting for ~1.3 million deaths in 2017.
296 idence of active TB following infection with Mtb and were subsequently either treated with 3HP (n = 7
297              Notably, in vivo infection with Mtb led to sustained DSBs and ATM activation during chro
298 ction and possible avenues to interfere with Mtb infection, including vitamin B5 supplementation.Anal
299 bserved that Hsp20 is poorly expressed in WT Mtb and that its expression is greatly induced upon depl
300 ated lysosomal rewiring compared with the WT Mtb in both in vitro and in vivo infections.

 
Page Top